For example, in ovarian cancer cells both PIK3CA mutations and PTEN deficiency have been reported to predict PI3K pathway inhibitor response (Ihle et al., 2009; Di Nicolantonio et al., 2010; Meuillet et al., 2010; Santiskulvong et al., 2011; Tanaka et al., 2011; Meric-Bernstam et al., 2012), whereas in breast cancer the associations between PTEN loss of function and response are less clear (She et al., 2008; Brachmann et al., 2009; Lehmann et al., 2011; Sanchez et al., 2011; Tanaka et al., 2011; Weigelt et al., 2011), which will be discussed in greater detail below. This evidence concerns the gene PTEN and breast cancer.